Halozyme Therapeutics Inc., an oncology biotech in San Diego, reported that its chief financial officer, David Ramsay, will retire this summer.
Laurie Stelzer will be his successor. She will assume CFO duties on June 15 and will work with Ramsay through a transition period.
Stelzer is an industry veteran, most recently serving as senior vice president of finance for research and development, technical operations and business development at Shire Plc, and previously as division CFO for regenerative medicine.
Before Shire, Stelzer spent 15 years at Amgen, in senior leadership roles in finance and business development with responsibilities including the U.S., Canada and international markets, ultimately serving as the company's acting treasurer.
Earlier this week, Halozyme announced a new global collaboration with drug giant AbbVie, and presented interim data on its phase 2 study of PEGPH20 for the potential treatment of patients with metastatic pancreatic cancer.
Halozyme plans to initiate its pivotal phase 3 study of PEGPH20 in the first quarter of 2016.